Immunogenicity of an additional mRNA-1273 SARS-CoV-2 vaccination in people with HIV with hyporesponse after primary vaccination

Marlou J Jongkees, Daryl Geers, Kathryn S Hensley, Wesley Huisman, Corine H GeurtsvanKessel, Susanne Bogers, Lennert Gommers, Grigorios Papageorgiou, Simon P Jochems, Jan G den Hollander, Emile F Schippers, Heidi S M Ammerlaan, Wouter F W Bierman, Marc van der Valk, Marvin A H Berrevoets, Robert Soetekouw, Nienke Langebeek, Anke H W Bruns, Eliane M S Leyten, Kim C E SigaloffMarit G A van Vonderen, Corine E Delsing, Judith Branger, Peter D Katsikis, Yvonne M Mueller, Rory D de Vries, Bart J A Rijnders, Kees Brinkman, Casper Rokx, Anna H E Roukens

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
12 Downloads (Pure)


BACKGROUND: The COVIH study is a prospective coronavirus disease 2019 (COVID-19) vaccination study in 1154 people with HIV (PWH), of whom 14% showed reduced antibody levels after primary vaccination. We evaluated whether an additional vaccination boosts immune responses in these hyporesponders. METHODS: The primary end point was the increase in antibodies 28 days after additional mRNA-1273 vaccination. Secondary end points included neutralizing antibodies, S-specific T-cell and B-cell responses, and reactogenicity. RESULTS: Of the 66 participants, 40 previously received 2 doses ChAdOx1-S, 22 received 2 doses BNT162b2, and 4 received a single dose Ad26.COV2.S. The median age was 63 years (interquartile range [IQR], 60-66), 86% were male, and median CD4+ T-cell count was 650/μL (IQR, 423-941). The mean S1-specific antibody level increased from 35 binding antibody units (BAU)/mL (95% confidence interval [CI], 24-46) to 4317 BAU/mL (95% CI, 3275-5360) (P < .0001). Of all participants, 97% showed an adequate response and the 45 antibody-negative participants all seroconverted. A significant increase in the proportion of PWH with ancestral S-specific CD4+ T cells (P = .04) and S-specific B cells (P = .02) was observed. CONCLUSIONS: An additional mRNA-1273 vaccination induced a robust serological response in 97% of PWH with a hyporesponse after primary vaccination. Clinical Trials Registration. EUCTR2021-001054-57-N.

Original languageEnglish
Pages (from-to)651-662
Number of pages12
JournalThe Journal of infectious diseases
Issue number5
Early online date19 Nov 2022
Publication statusPublished - 1 Mar 2023

Bibliographical note

Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.


Dive into the research topics of 'Immunogenicity of an additional mRNA-1273 SARS-CoV-2 vaccination in people with HIV with hyporesponse after primary vaccination'. Together they form a unique fingerprint.

Cite this